
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics - Kalido whitepaper






